



## **ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference**

### **Company CEO Invited to Speak and Join Conference Faculty for ICDS 2022**

On the basis of clinical success and acknowledged leadership in the field of celiac disease, the organizers of the International Celiac Disease Symposium (ICDS) have invited Jack Syage PhD, CEO of ImmunogenX, to deliver a panel talk and join the Conference Faculty. ICDS is held internationally every other year and is considered the premier conference for celiac disease. This year it will be held in Sorrento Italy from October 19-22, 2022.

Dr. Syage will present results from the recent successful NIH/NCCIH funded\* CeliacShield™ trial (NCT03585478) on the drug candidate latiglutenase conducted at the Mayo Clinic under Principal Investigator Joseph Murray MD. This study continues to draw strong attention following the selection of this work as both a Lecture Presentation and a Poster of Distinction at the 2022 Digestive Disease Week® (DDW) Conference, the foremost gastroenterological meeting in the world, being held at the San Diego Convention Center, San Diego, CA on May 21-24.

Jennifer Sealey Voyksner PhD, CSO of ImmunogenX, remarks "Our team continues to be recognized as a leader in the development of therapeutic options for individuals suffering from celiac disease. It is gratifying that the community views our drug candidate latiglutenase as a top prospect for meeting this unmet need."

*\* The content of this news release is solely the responsibility of ImmunogenX and does not necessarily represent the official views of the National Institutes of Health.*

### **About ImmunogenX**

ImmunogenX, Inc. is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel™) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. [www.immunogenx.com](http://www.immunogenx.com)

### **For further information please contact**

Matthew Dickason, MBA  
Chief Operating Officer  
(949) 679-0900

[mdickason@immunogenx.com](mailto:mdickason@immunogenx.com)